N/A N=11 Behavioral Activation for Post-Stroke Sedentary Behavior Using Telehealth
Stroke · Stroke, Ischemic · Stroke Hemorrhagic
Primary: Incidence of Treatment-Emergent Adverse Events — 2; 0 adverse events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=61 Beacon Sensors and Telerehabilitation for Low Vision
Low Vision
Primary: Activity Inventory — 0.44; 0.43 logit — p=0.73
N/A N=34 Depression and Pain Perseverance Through Empowered Recovery Intervention
Pain · Depressive Symptoms · Frailty
Primary: Pain Intensity as Assessed by the Patient Reported Outcomes Measurement Information System (PROMIS) — 6.75; 7.29; 6.64; 7.00 score on a scale
N/A N=604 A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
Breast Cancer
Primary: Progression-Free Survival (PFS) — 30.6 Months
N/A N=195 Toolkit for Optimal Recovery After Orthopedic Injury
Acute Orthopedic Injury
Primary: Feasibility of Recruitment Among All Patients — 210 Participants
N/A N=24 Shift-and-persist and Cardiometabolic Markers Among Women in Puerto Rico
Psychological Distress · Cardiometabolic Syndrome
Primary: Rates of Recruitment and Retention — 24; 24; 23 Participants
Phase 1 N=3 Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors
Brain Neoplasms, Primary Malignant
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants
Phase 2 N=42 Temozolomide Chronotherapy for High Grade Glioma
Glioma · Glioblastoma Multiforme
Primary: Feasibility of Patient Treatment Compliance as Measured by Number of Participants Who Were at Least 80% Compliance With Assigned Administration Time — 17; 15 Participants
Phase 1 N=19 Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor
Advanced Solid Tumor · Lung Cancer · Pancreas Cancer
Primary: Safety and Tolerability Assessment of CNSI-Fe(II) — 0; 0; 1; 0 Participants
Phase 1 N=127 Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults
HIV Infections
Primary: Number of Participants Reporting Local Solicited Adverse Events Signs and Symptoms: Pain and/or Tenderness — 0; 0; 1; 5 Participants
N/A N=119 A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo Aspiration System
Lower Extremity Acute Limb Ischemia · LE ALI
Primary: Target Limb Salvage Rate — 109 Participants
N/A N=437 OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
Opioid-use Disorder
Primary: Treatment Success Rate — 70; 67 Participants — p=0.7326
N/A N=16 Low Level Laser Therapy for Radiation Induced Dermatitis in H & N Squamous Cell Carcinoma
Radiation Dermatitis
Primary: Grade 3 or Higher Adverse Events — 9 Participants
Phase 4 N=60 Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?
Schizophrenia · Schizoaffective Disorder
Primary: Change in Cognition and Psychopathology Disorders as Measured on the MATRICS Consensus Cognitive Battery (MCCB) — 14.1; 14.3 units on a scale
Phase 2 N=92 A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
Glabellar Lines
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 7; 15; 9; 2 Participants